Completed PHASE2 INTERVENTIONAL 2-arm NCT00476931

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderate to Severe Diabetic Neuropathy and Unmeasurable Nerve Conduction Velocity

Sponsor: Sangamo Therapeutics

Conditions Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetic Polyneuropathy

Interventions Placebo SB-509

Updated 7 times since 2017 Last updated: Oct 30, 2012 Started: May 31, 2007 Primary completion: Jul 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2 and is currently completed. Sangamo Therapeutics leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sangamo Therapeutics

Data source: Sangamo Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Bradenton, United States , Duncansville, United States , Houston, United States , Kansas City, United States , La Jolla, United States , Lakewood, United States , Las Vegas, United States , Lomita, United States , Mexico City, Mexico and 9 more locations